Showing 8671-8680 of 18584 results for "".
- Harnessing Mathematical Models to Unravel Mood Dynamics in Bipolar Disorderhttps://reachmd.com/news/harnessing-mathematical-models-to-unravel-mood-dynamics-in-bipolar-disorder/2484104/A new Springer review shows mathematical modeling of mood dynamics clarifies clinically relevant features of bipolar disorder and holds promise for i
- The Potential Role of Magnesium Supplementation in Depression Managementhttps://reachmd.com/news/the-potential-role-of-magnesium-supplementation-in-depression-management/2475529/Emerging clinical studies, including a systematic review and meta-analysis, suggest that magnesium supplementation may have a modest effect on depressive symptoms, but further research i
- C5aR1: A Critical Biomarker for Metastasis in Cutaneous Squamous Cell Carcinomahttps://reachmd.com/news/c5ar1-a-critical-biomarker-for-metastasis-in-cutaneous-squamous-cell-carcinoma/2474919/Recent identification of complement component 5a receptor 1 (C5aR1) as a critical metastasis biomarker may improve risk stratification and patient management i
- Are Chemical Sunscreens Safe? Dermatologists Reveal What the Science Really Sayshttps://reachmd.com/news/are-chemical-sunscreens-safe-dermatologists-reveal-what-the-science-really-says/2468250/With so many claims flying around TikTok, it's no wonder people are confused — and concerned — about the safety of chemical sunscreens."I just had a patien
- Targeting Regulated Cell-Death Pathways in Severe Cutaneous Adverse Reactionshttps://reachmd.com/news/targeting-regulated-cell-death-pathways-in-severe-cutaneous-adverse-reactions/2484242/Investigators have linked formyl peptide receptor 1 (FPR1)–dependent necroptosis to epidermal cell death in SJS/TEN–type reactions and described an FPR1-targeted inhibitor that reduced
- New Horizons in COPD Management: Dupilumab and Ensifentrine Breakthroughshttps://reachmd.com/news/new-horizons-in-copd-management-dupilumab-and-ensifentrine-breakthroughs/2475985/Despite progress in conventional treatments, COPD patients with type 2 inflammation continue to face recurrent exacerbations and unchecked dyspnea, highlighting an urgent need for novel interventions.Although Dupilumab is not yet FDA approved for COPD, the biologics license application for
- Enhancing Diagnostics in Genetic Disorders and Oncology with Quantitative MRIhttps://reachmd.com/news/enhancing-diagnostics-in-genetic-disorders-and-oncology-with-quantitative-mri/2474956/Timely identification of subtle structural changes in conditions such as neurofibromatosis type 1 and uterine cancer remains a critical diagnostic challenge. Quantitative MRI is emerging as a promising tool to help pinpoint these nuances in g
- Pilot Study Suggests Selumetinib's Potential for Cutaneous Neurofibromashttps://reachmd.com/news/pilot-study-suggests-selumetinibs-potential-for-cutaneous-neurofibromas/2471373/A new nonrandomized pilot trial suggested the MEK inhibitor selumetinib was associated with a reduction in the size of cutaneous neurofibromas in patients with Neurofibromatosis Type 1 (NF1). These study, published as a brief rep
- Building Bridges Between Cells for Brain Healthhttps://reachmd.com/news/building-bridges-between-cells-for-brain-health/2467558/The brain contains many cell types, from the prominent neurons to the lesser-known microglia. The latter are integral to the brain’s immune system and play a crucial role as the brain’s cleanup crew. A recent study conducted by researchers from the
- Personalized Vaccine for Liver Cancer Shows Promise in Clinical Trialhttps://reachmd.com/news/personalized-vaccine-for-liver-cancer-shows-promise-in-clinical-trial/2467322/Adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patients with hepatocellular carcinoma, the most common type of liver cancer, according to a clinical trial